Post-earnings recap
Reported
Wed, Feb 8, 2012
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
100%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Neurocrine Biosciences reported a positive EPS surprise, which indicates better-than-expected profitability. However, the stock fell by 0.95%, likely due to a lack of revenue data and no guidance for the future. Investors may be cautious as they await more information on the company's growth plans.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.02 | N/A | +100.00% |
| Revenue | N/A | N/A | N/A |
Management expressed satisfaction with the positive EPS surprise. They emphasized their commitment to exploring growth opportunities.
We are pleased with our EPS performance this quarter.
Future growth opportunities remain a focus for us.